A mutation in a microglial receptor, termed triggering receptor expressed on myeloid cells 2 (TREM2), which is a receptor for ApoE, has been shown to be associated with increased risk of developing AD [154, 155]. This evidence concerns the gene APOE and Alzheimer disease.